Toshikatsu Okumura Selected Research

Corticotropin-Releasing Hormone

4/2022	Pathophysiological Commonality Between Irritable Bowel Syndrome and Metabolic Syndrome: Role of Corticotropin-releasing Factor-Toll-like Receptor 4-Proinflammatory Cytokine Signaling.
7/2021	Phlorizin attenuates visceral hypersensitivity and colonic hyperpermeability in a rat model of irritable bowel syndrome.
7/2021	EMA401, an angiotensin II type 2 receptor antagonist blocks visceral hypersensitivity and colonic hyperpermeability in rat model of irritable bowel syndrome.
11/2020	Imipramine improves visceral sensation and gut barrier in rat models of irritable bowel syndrome.
1/2020	Losartan improves visceral sensation and gut barrier in a rat model of irritable bowel syndrome.
12/2019	Butyrate inhibits visceral allodynia and colonic hyperpermeability in rat models of irritable bowel syndrome.
12/2017	Repeated water avoidance stress induces visceral hypersensitivity: Role of interleukin-1, interleukin-6, and peripheral corticotropin-releasing factor.
1/2017	Lipopolysaccharide induces visceral hypersensitivity: role of interleukin-1, interleukin-6, and peripheral corticotropin-releasing factor in rats.
12/2015	Colorectal distention induces acute and delayed visceral hypersensitivity: role of peripheral corticotropin-releasing factor and interleukin-1 in rats.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Toshikatsu Okumura Research Topics

Disease

34	Neoplasms (Cancer) 10/2022 - 07/2002
23	Irritable Bowel Syndrome (Syndrome, Irritable Bowel) 10/2022 - 02/2015
15	Hypersensitivity (Allergy) 08/2022 - 02/2015
11	Pancreatic Neoplasms (Pancreatic Cancer) 01/2020 - 01/2004
11	Hyperalgesia 01/2020 - 12/2014
8	Stomach Neoplasms (Stomach Cancer) 01/2022 - 07/2002
5	Colorectal Neoplasms (Colorectal Cancer) 10/2022 - 01/2020
5	Neoplasm Metastasis (Metastasis) 09/2021 - 01/2019
5	Adenocarcinoma 07/2021 - 01/2019
5	Gastrointestinal Diseases (Functional Gastrointestinal Disorders) 01/2020 - 01/2008
5	Fatty Liver 01/2018 - 10/2005
4	Hepatocellular Carcinoma (Hepatoma) 12/2022 - 01/2004
4	Inflammation (Inflammations) 04/2022 - 01/2021
4	Visceral Pain 07/2021 - 02/2016
4	Colitis 01/2021 - 08/2017
4	Nociceptive Pain 01/2018 - 02/2016
3	Fatigue 12/2022 - 01/2020
3	Hemorrhage 10/2022 - 01/2010
3	Diarrhea 06/2022 - 02/2016
3	Ulcerative Colitis 08/2021 - 01/2020
3	Carcinogenesis 01/2021 - 01/2020
3	Non-alcoholic Fatty Liver Disease 06/2020 - 01/2018
2	Insulin Resistance 04/2022 - 05/2009
2	Obesity 04/2022 - 05/2009
2	Liver Diseases (Liver Disease) 03/2022 - 08/2017
2	Crohn Disease (Crohn's Disease) 01/2022 - 12/2018
2	Disease Progression 09/2021 - 03/2015
2	Lymphatic Metastasis 09/2021 - 01/2019
2	Ascites 08/2021 - 08/2017
2	Sepsis (Septicemia) 08/2021 - 12/2020
2	Carcinoma (Carcinomatosis) 01/2021 - 12/2020
2	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2021 - 03/2015
2	Neoplasms, Cystic, Mucinous, and Serous 12/2020 - 01/2018
2	Fibrosis (Cirrhosis) 01/2018 - 08/2017
2	Abdominal Pain (Pain, Abdominal) 08/2017 - 02/2016
2	Constipation 09/2016 - 02/2016

Drug/Important Bio-Agent (IBA)

16	LipopolysaccharidesIBA 08/2022 - 01/2017
10	CytokinesIBA 08/2022 - 01/2017
10	PPAR gammaIBA 03/2010 - 07/2002
9	Corticotropin-Releasing HormoneIBA 04/2022 - 12/2015
8	Messenger RNA (mRNA)IBA 10/2022 - 07/2002
7	Proteins (Proteins, Gene)FDA Link 07/2021 - 07/2002
6	OrexinsIBA 04/2021 - 11/2005
6	LigandsIBA 02/2010 - 07/2002
6	Troglitazone (Rezulin)FDA Link 03/2009 - 07/2002
5	Corticotropin-Releasing Hormone Receptors (Corticotropin Releasing-Hormone Receptor)IBA 08/2022 - 12/2014
5	Biomarkers (Surrogate Marker)IBA 08/2021 - 03/2010
4	Naloxone (Narcan)FDA LinkGeneric 07/2021 - 01/2018
4	LipidsIBA 01/2018 - 10/2005
4	ThiazolidinedionesIBA 11/2010 - 10/2009
4	Gemcitabine FDA Link 10/2009 - 03/2004
3	Heterogeneous-Nuclear Ribonucleoproteins (Informatin)IBA 10/2022 - 01/2020
3	Small Interfering RNA (siRNA)IBA 10/2022 - 06/2020
3	astressinIBA 08/2022 - 12/2017
3	Colchicine FDA LinkGeneric 06/2022 - 12/2020
3	MucinsIBA 01/2022 - 09/2009
3	Immune Checkpoint InhibitorsIBA 01/2022 - 06/2020
3	NivolumabIBA 01/2022 - 01/2019
3	PolyphosphatesIBA 11/2021 - 01/2020
3	Pharmaceutical PreparationsIBA 01/2021 - 02/2017
3	FerrichromeIBA 01/2021 - 06/2017
3	IronIBA 01/2020 - 06/2017
3	Interleukin-1 (Interleukin 1)IBA 12/2017 - 12/2015
3	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 11/2010 - 06/2005
3	p38 Mitogen-Activated Protein KinasesIBA 09/2005 - 03/2004
2	Warfarin (Coumadin)FDA LinkGeneric 10/2022 - 01/2010
2	Interleukin 1 Receptor Antagonist Protein (Anakinra)FDA Link 08/2022 - 11/2018
2	Interleukin-1 Receptors (Interleukin 1 Receptor)IBA 08/2022 - 11/2018
2	Toll-Like Receptors (Toll-Like Receptor)IBA 04/2022 - 07/2021
2	Toll-Like Receptor 4IBA 04/2022 - 11/2018
2	AntibodiesIBA 07/2021 - 01/2021
2	Evans Blue (Blue, Evans)FDA Link 07/2021 - 11/2020
2	RNA-Binding Proteins (RNA-Binding Protein)IBA 06/2021 - 01/2020
2	Cisplatin (Platino)FDA LinkGeneric 01/2021 - 01/2020
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2021 - 05/2009
2	RNA (Ribonucleic Acid)IBA 01/2021 - 01/2020
2	Dextran SulfateIBA 01/2021 - 01/2021
2	DNA (Deoxyribonucleic Acid)IBA 12/2020 - 01/2020
2	RibonucleoproteinsIBA 06/2020 - 01/2020
2	Transaminases (Aminotransferases)IBA 01/2020 - 01/2006
2	Adenosine (Adenocard)FDA LinkGeneric 01/2020 - 03/2016
2	SteroidsIBA 06/2019 - 01/2019
2	Prednisolone (Predate)FDA LinkGeneric 06/2019 - 01/2010
2	Metformin (Glucophage)FDA LinkGeneric 01/2019 - 02/2017
2	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2019 - 01/2018
2	NG-Nitroarginine Methyl Ester (L-NAME)IBA 01/2019 - 01/2018
2	Interleukin-6 (Interleukin 6)IBA 12/2017 - 01/2017
2	TegafurIBA 08/2017 - 01/2006
2	UracilIBA 08/2017 - 01/2006
2	Anti-Bacterial Agents (Antibiotics)IBA 08/2017 - 01/2010
2	ramosetron (Nasea)IBA 09/2016 - 02/2016
2	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 12/2011 - 01/2004
2	Cadherins (E-Cadherin)IBA 11/2010 - 03/2009
2	Claudin-4IBA 11/2010 - 03/2009

Therapy/Procedure

16	Therapeutics 06/2022 - 03/2004
6	Drug Therapy (Chemotherapy) 01/2022 - 06/2018
3	Chemoradiotherapy 01/2021 - 08/2016
3	Gastrectomy 01/2021 - 09/2019
2	Lymph Node Excision (Lymph Node Dissection) 01/2021 - 08/2016
2	Subcutaneous Injections 01/2020 - 11/2018